BioSpace News Archive

Bridge Biotherapeutics (KQ288330), presented the non-clinical study results of ‘BBT-301', a novel, small molecular inhibitor of KCa 3.1, and ‘BBT-209', an endogenous GPCR19 agonist, both being developed as novel IPF treatments, at the 6th Annual IPF Summit (August 29 - September 1, 2022), in Boston, MA.

Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced the appointment of Helen S. Kim, MBA, to its Board of Directors.

Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells Fargo Securities Healthcare Conference taking place in Everett, MA from September 7-9, 2022.

Alpha Tau Medical Ltd. announced that Peter Melnyk, a member of its board of directors, has resigned from the Company’s Board of Directors in order to assume the full-time position of Alpha Tau’s Chief Commercial Officer.

DexCom, Inc. announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor conferences.

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced that management plans to participate in four upcoming investor conferences.

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to three new employees to purchase an aggregate of 72,200 shares of the Company’s common stock, effective as of September 1, 2022.

Danaher Corporation will host a live video webcast of its Bioprocessing Investor and Analyst Meeting at Cytiva on September 15, 2022 beginning at approximately 12:00 p.m. ET.

Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, at 2:55 p.m. Eastern Time.